Evaluation of combinations of 4=-ethynyl-2-fluoro-2=-deoxyadenosine with clinically used antiretroviral drugs

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 9, 2013, Pages 4554-4558

  Hachiya, Atsuko ^a,b,i   Reeve, Aaron B ^c   Marchand, Bruno ^a   Michailidis, Eleftherios ^a   Ong, Yee Tsuey ^a   Kirby, Karen A ^a   Leslie, Maxwell D ^a   Oka, Shinichi ^b   Kodama, Eiichi N ^d   Rohan, Lisa C ^e,f   Mitsuya, Hiroaki ^g,h   Parniak, Michael A ^c   Sarafianos, Stefan G ^a  

^a University of Missouri   (United States)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d TOHOKU UNIVERSITY   (Japan)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g KUMAMOTO UNIVERSITY   (Japan)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4' ETHYNYL 2 FLUORO 2' DEOXYADENOSINE; ADENOSINE DEAMINASE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; FOOD AND DRUG ADMINISTRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL;

EID: 84882363875     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00283-13     Document Type: Article

References (32)

1. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Gunthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. 2012. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308:387-402.
2. James JS. 2004. FDA approves two combination pills, Epzicom and Truvada; comment on commercial race to once-a-day nucleosides. AIDS Treat News 403:6. http://www.aidsnews.org/2004/08/epzicom-truvada .html.
3. Killingley B, Pozniak A. 2007. The first once-daily single-tablet regimen for the treatment of HIV-infected patients. Drugs Today 43:427-442.
4. Borroto-Esoda K, Vela JE, Myrick F, Ray AS, Miller MD. 2006. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Antivir. Ther. 11:377-384.
5. Feng JY, Ly JK, Myrick F, Goodman D, White KL, Svarovskaia ES, Borroto-Esoda K, Miller MD. 2009. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. Retrovirology 6:44. doi:10.1186/1742-4690-6-44.
6. Kawamoto A, Kodama E, Sarafianos SG, Sakagami Y, Kohgo S, Kitano K, Ashida N, Iwai Y, Hayakawa H, Nakata H, Mitsuya H, Arnold E, Matsuoka M. 2008. 2=-Deoxy-4=-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int. J. Biochem. Cell Biol. 40:2410-2420.
7. Michailidis E, Marchand B, Kodama EN, Singh K, Matsuoka M, Kirby KA, Ryan EM, Sawani AM, Nagy E, Ashida N, Mitsuya H, Parniak MA, Sarafianos SG. 2009. Mechanism of inhibition of HIV-1 reverse transcriptase by 4=-ethynyl-2-fluoro-2= -deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J. Biol. Chem. 284:35681-35691.
8. Kirby KA, Singh K, Michailidis E, Marchand B, Kodama EN, Ashida N, Mitsuya H, Parniak MA, Sarafianos SG. 2011. The sugar ring conformation of 4=-ethynyl-2-fluoro-2=-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase. Cell Mol. Biol. 57:40-46.
9. Murphey-Corb M, Rajakumar P, Michael H, Nyaundi J, Didier PJ, Reeve AB, Mitsuya H, Sarafianos SG, Parniak MA. 2012. Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4=-ethynyl-2-fluoro-2=-deoxyadenosine in vitro and in vivo. Antimicrob. Agents Chemother. 56:4707-4712.
10. Hattori S, Ide K, Nakata H, Harada H, Suzu S, Ashida N, Kohgo S, Hayakawa H, Mitsuya H, Okada S. 2009. Potent activity of a nucleoside reverse transcriptase inhibitor, 4=-ethynyl-2-fluoro-2=-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice. Antimicrob. Agents Chemother. 53:3887-3893.
11. Prichard MN, Prichard LE, Shipman C, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob. Agents Chemother. 37:540-545.
12. Prichard MN, Shipman C, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14:181-205.
13. Chou TC, Talalay P. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
14. Pirrone V, Thakkar N, Jacobson JM, Wigdahl B, Krebs FC. 2011. Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob. Agents Chemother. 55:1831-1842.
15. Chang CN, Skalski V, Zhou JH, Cheng YC. 1992. Biochemical pharmacology of-and-2=,3=-dideoxy-3=-thiacytidine as anti-hepatitis B virus agents. J. Biol. Chem. 267:22414-22420.
16. Sabini E, Hazra S, Konrad M, Lavie A. 2007. Nonenantioselectivity property of human deoxycytidine kinase explained by structures of the enzyme in complex with L-and D-nucleosides. J. Med. Chem. 50:3004-3014.
17. Hachiya A, Kodama EN, Schuckmann MM, Kirby KA, Michailidis E, Sakagami Y, Oka S, Singh K, Sarafianos SG. 2011. K70Q adds high-level tenofovir resistance to "Q151M complex" HIV reverse transcriptase through the enhanced discrimination mechanism. PLoS One 6:e16242. doi:10.1371/journal.pone.0016242.
18. Kirby KA, Marchand B, Ong YT, Ndongwe TP, Hachiya A, Michailidis E, Leslie MD, Sietsema DV, Fetterly TL, Dorst CA, Singh K, Wang Z, Parniak MA, Sarafianos SG. 2012. Structural and inhibition studies of the RNase H function of xenotropic murine leukemia virus-related virus reverse transcriptase. Antimicrob. Agents Chemother. 56:2048-2061.
19. Nakata H, Amano M, Koh Y, Kodama E, Yang G, Bailey CM, Kohgo S, Hayakawa H, Matsuoka M, Anderson KS, Cheng YC, Mitsuya H. 2007. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4=-ethynyl-2-fluoro-2=-deoxyadenosine. Antimicrob. Agents Chemother. 51:2701-2708.
20. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-1174.
21. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapia M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernandez T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallas EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363:2587-2599.
22. Richman D, Rosenthal AS, Skoog M, Eckner RJ, Chou TC, Sabo JP, Merluzzi VJ. 1991. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob. Agents Chemother. 35:305-308.
23. Brennan TM, Taylor DL, Bridges CG, Leyda JP, Tyms AS. 1995. The inhibition of human immunodeficiency virus type 1 in vitro by a nonnucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. Antiviral Res. 26:173-187.
24. King RW, Klabe RM, Reid CD, Erickson-Viitanen SK. 2002. Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. Antimicrob. Agents Chemother. 46: 1640-1646.
25. Maga G, Hubscher U, Pregnolato M, Ubiali D, Gosselin G, Spadari S. 2001. Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and D-and L-(beta)-dideoxynucleoside triphosphate analogs. Antimicrob. Agents Chemother. 45:1192-1200.
26. Borkow G, Arion D, Wainberg MA, Parniak MA. 1999. The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3=-azido-3=-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 43:259-263.
27. Odriozola L, Cruchaga C, Andreola M, Dolle V, Nguyen CH, Tarrago-Litvak L, Perez-Mediavilla A, Martinez-Irujo JJ. 2003. Non-nucleoside inhibitors of HIV-1 reverse transcriptase inhibit phosphorolysis and resensitize the 3=-azido-3=-deoxythymidine (AZT)-resistant polymerase to AZT-5=-triphosphate. J. Biol. Chem. 278:42710-42716.
28. Cruchaga C, Odriozola L, Andreola M, Tarrago-Litvak L, Martinez-Irujo JJ. 2005. Inhibition of phosphorolysis catalyzed by HIV-1 reverse transcriptase is responsible for the synergy found in combinations of 3=-azido-3=-deoxythymidine with nonnucleoside inhibitors. Biochemistry 44:3535-3546.
29. Basavapathruni A, Bailey CM, Anderson KS. 2004. Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs. J. Biol. Chem. 279:6221-6224.
30. Radzio J, Sluis-Cremer N. 2008. Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. Mol. Pharmacol. 73:601-606.
31. Shaw-Reid CA, Feuston B, Munshi V, Getty K, Krueger J, Hazuda DJ, Parniak MA, Miller MD, Lewis D. 2005. Dissecting the effects of DNA polymerase and ribonucleaseHinhibitor combinations on HIV-1 reversetranscriptase activities. Biochemistry 44:1595-1606.
32. Parikh UM, Koontz DL, Chu CK, Schinazi RF, Mellors JW. 2005. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob. Agents Chemother. 49:1139-1144.